PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth of 22.68% while RVPH is zero. Bruce Berkowitz would see if small gains can be scaled further.
22.68%
Operating income growth of 22.68% while RVPH is zero. Bruce Berkowitz would see if this modest edge can become significant.
22.99%
Net income growth of 22.99% while RVPH is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
38.32%
EPS growth of 38.32% while RVPH is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
38.32%
Diluted EPS growth of 38.32% while RVPH is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
24.80%
Share change of 24.80% while RVPH is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
24.80%
Diluted share change of 24.80% while RVPH is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
22.87%
OCF growth of 22.87% while RVPH is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
22.60%
FCF growth of 22.60% while RVPH is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
19.53%
OCF/share CAGR of 19.53% while RVPH is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
73.45%
3Y OCF/share CAGR of 73.45% while RVPH is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-5088.50%
Negative 10Y net income/share CAGR while RVPH is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
Net income/share CAGR of 66.11% while RVPH is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
78.36%
3Y net income/share CAGR of 78.36% while RVPH is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
2877.65%
Equity/share CAGR of 2877.65% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
75.50%
Equity/share CAGR of 75.50% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-75.29%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Negative asset growth while RVPH invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-36.19%
We have a declining book value while RVPH shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Our R&D shrinks while RVPH invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while RVPH invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.